

Subject:	Finance & Performance Committee Chair's Report
Presented by:	Hilary De Lyon – Lay Member (Audit)
Produced by:	Rob Bennett - Lay Member Audit & Finance
Submitted to:	NHS West Norfolk CCG Governing Body 24th May 2018
Purpose of Paper:	For noting

Key matters discussed at the Finance & Performance Committee meeting on 22 March 2018.

Introduction

The following is a summary of the key matters discussed at the Finance & Performance Committee meeting held on 22 March 2018. The minutes of the meeting will be available when approved at the next meeting.

The main focus of the meeting was on the CCG's performance in relation to A&E waiting times, Referral to Treatment times and Cancer 62 day GP referral to treatment. The Committee was also briefed on the financial results to the end of February 2018 and reviewed the latest financial plan for 2018/19.

Integrated Performance and Finance Report – February 2018

The Committee's attention was drawn to continuing concerns about the recent performance in relation to A&E Waiting Times, the Cancer 62 day GP referral to treatment and the Referral to Treatment (RTT) targets.

In the case of A&E Waiting Times, this is a major focus of attention given the current level of performance. The Committee was informed that this is a symptom of flow within the hospital.

The CCG is providing daily support to the QEH and there are procedures in place to escalate issues around discharging patients. Extra bed capacity is also being funded in the community.

The Committee noted the current level of performance on the overall RTT target was 82% compared with target of 92%. The Committee was informed that the QEH has provided it with a Remedial Action Plan for improving performance but that this plan needs more work on it. The revised plan will then form the basis for ongoing monitoring.

The Committee noted that the latest data for performance against the Cancer 62 day GP referral to treatment target is 80% and is still below the target of 85%. The Cancer Delivery Board has started meeting again and the CCG will continue to ensure that further work is undertaken to improve performance.

The Committee discussed the latest mental health performance data, noting that a number of areas are below the national targets. The Committee noted that there is a concern about meeting the dementia diagnosis target given the current level of performance.

The Interim Chief Financial Officer reported the CCG's financial results to the end of February 2018 compared with the budget. The overspend compared with budget is £5.4m. The main areas of overspending continue to be acute commissioning, Continuing Healthcare, Community Service and GP Prescribing. The forecast for the deficit at the end of the financial year is £7.3m which represents a variance from the original plan of £10.9m.

Financial Plan 2018/19

The Committee received an update to the financial plan for 2018/19.

The Committee was informed of the key features of the plan and the process by which it had been developed taking the forecast for 2017/18 as the starting point and the funding allocations received from NHS England. The Committee also recognised that the plan may be subject to change as the contractual arrangements for 2018/19 are still being finalised.

In essence, the financial plan is designed to deliver a deficit of £2m in 2018/19 as part of the medium term strategy to bring the CCG into financial balance by March 2020. The delivery of the QIPP target is critical to achieving this result. The QIPP programme will need to deliver spending reductions of £12.8m next year.

Following its discussion, the Committee agreed to recommend the financial plan for 2018/19 to the Governing Body for approval.

Closing Remarks

I would welcome feedback on the content of this report and if there are any queries, please email them to me via the CCG's website.

Rob Bennett

Chair

27 March 2018

KEY RISKS

Clinical: The Committee reviews mitigation with clinical quality risks as part of provider performance discussions, alongside the Patient Safety & Clinical Quality Committee.

Finance and Performance: The Committee's role is to review the effectiveness of mitigation strategies for all finance and performance risks.

Impact Assessment (environmental and equalities): N/a

Reputation: The Committee reviews the impact of risks on CCG's reputation as part of its role.

Legal: The Committee reviews the CCG's ability to meet statutory obligations.

Patient focus (if appropriate): The Committee reviews mitigation with clinical quality risks as part of provider performance discussions, alongside the Patient Safety & Clinical Quality Committee.

Reference to relevant Governing Body Assurance Framework (GBAF): All risks on GBAF

RECOMMENDATION: The Governing Body is asked to note the Chair's Report